To the Editor.—
This controversy concerning the photoinactivation of Herpesvirus hominis reminds us of a story, too—the cyclamate story. We all recall the furor over the carcinogenicity of cyclamates that resulted in a Food and Drug Administration scorched earth holocaust with the soft drink industry. Now as the clouds of war are clearing, new studies have shown that cyclamates have a protective rather than an enhancing effect when they are administered coincidentally with certain carcinogens. Here at Baylor we believe that, despite Dr. Rapp's recent reports, photodynamic inactivation of herpes simplex virus (HSV) will eventually prove to have a protective rather than an enhancing effect on HSV carcinogenesis. However, we must agree fully with Dr. Pass that at this point the data on carcinogenesis are inadequate to arrive at a strictly scientific conclusion on either side of the argument.So let us review briefly Dr. Rapp's work on which the
Jarratt M, Hubler WR, Melnick JL, Knox JM. Photoinactivation Therapy and Herpes Simplex-Reply. Arch Dermatol. 1974;110(4):642. doi:10.1001/archderm.1974.01630100090038
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: